Influence of Gender on the Plasma-Effect site equilibration time of propofol anesthetic and Cisatracurium Besylate neuromuscular blocking agent. A pilot study. - Gender Anesthesia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-017921-20-AT

Enrollment

Registered

2010-08-16

Start date

2010-09-16

Completion date

Unknown

Last updated

2016-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

effect of Gender on Pharmacokinetics of Propofol and cisatracurium

Interventions

Trade Name: Nimbex Injektionslösung 2 mg / ml Product Name: Cisatracurium Pharmaceutical Form: Solution for injection INN or Proposed INN: CISATRACURIUM BESILATE CAS Number: 96946-42-8 Other descripti

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Twenty consecutive male and twenty female, ASA I-II patients, aged 18-45 yr, undergoing general anaesthesia for scheduled elective urological or kidney surgery will be recruited in the study. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Potential participants with body mass index 26 kg/m2, or patients on treatment with drugs thought to interfere with neuromuscular transmission (aminiglycosides antibiotics, antiarrhythmics, antiepileptics, anticonvulsant, diuretics, lithium and magnesium) or patients scheduled to receive propofol Total Intravenous Anesthesia (TIVA) will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
Main Objective: Pharmacokinetics gender differences in Propofol and cisatracurium;Secondary Objective: None;Primary end point(s): Pharmacokinetic parameters of cisatracurium and propofol	—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026